Literature DB >> 1675106

Quantitation of albumin and alpha-1-acid glycoprotein in human cervical mucus.

I G Salas Herrera1, R M Pearson, P Turner.   

Abstract

1. Concentrations of albumin and alpha-1-acid glycoprotein (AGP) in human cervical mucus have been measured by a radial immunodiffusion technique. 2. The cervical mucus samples were obtained from women on combined oral contraceptives (Group A) and from women not taking this medication (Group B). In group A the mean level of albumin was 75.6 (range 22-198) mg l-1 and for AGP 6.5 (range 3-12) mg l-1. In group B the mean level of albumin was 72.9 (range 22-148) mg l-1 and for AGP 6.6 (range 3-14) mg l-1. 3. The levels of albumin and AGP in cervical mucus were less than 1% of the concentration in serum and were not affected by combined oral contraceptives. 4. The clinical and toxicological consequences of these observations, in terms of the disposition of drugs and other chemicals in the female genital tract, await elucidation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1675106     DOI: 10.1177/096032719101000209

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  9 in total

1.  Secretion of drugs into the human female genital tract.

Authors:  I G Salas-Herrera; P Turner; R M Pearson
Journal:  Postgrad Med J       Date:  1991-08       Impact factor: 2.401

2.  Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.

Authors:  Julie B Dumond; Rosa F Yeh; Kristine B Patterson; Amanda H Corbett; Byung Hwa Jung; Naser L Rezk; Arlene S Bridges; Paul W Stewart; Myron S Cohen; Angela D M Kashuba
Journal:  AIDS       Date:  2007-09-12       Impact factor: 4.177

Review 3.  Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.

Authors:  Christine R Trezza; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2014-07       Impact factor: 6.447

Review 4.  HIV prevention by oral preexposure prophylaxis.

Authors:  Walid Heneine; Angela Kashuba
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

Review 5.  Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.

Authors:  Mackenzie L Cottrell; Tanja Hadzic; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2013-11       Impact factor: 6.447

Review 6.  Pharmacologic opportunities for HIV prevention.

Authors:  M R Nicol; A D M Kashuba
Journal:  Clin Pharmacol Ther       Date:  2010-09-29       Impact factor: 6.875

Review 7.  Pharmacokinetics of antiretrovirals in mucosal tissue.

Authors:  Mackenzie L Cottrell; Nithya Srinivas; Angela D M Kashuba
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-03-22       Impact factor: 4.481

8.  Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.

Authors:  Julie B Dumond; Melanie R Nicol; Racheal N Kendrick; Samira M Garonzik; Kristine B Patterson; Myron S Cohen; Alan Forrest; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

9.  Single and multiple dose pharmacokinetics of dolutegravir in the genital tract of HIV-negative women.

Authors:  Jessica L Adams; Kristine B Patterson; Heather M A Prince; Craig Sykes; Benjamin N Greener; Julie B Dumond; Angela D M Kashuba
Journal:  Antivir Ther       Date:  2013-07-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.